comparemela.com

Latest Breaking News On - Minvest partners - Page 1 : comparemela.com

Epoch Investment Partners Inc Boosts Stock Position in Edwards Lifesciences Co (NYSE:EW)

Epoch Investment Partners Inc. grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 82.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 589,070 shares of the medical research company’s stock after purchasing an additional 266,292 […]

Edwards Lifesciences Co (NYSE:EW) Shares Acquired by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 197.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,446,758 shares of the medical research company’s stock after acquiring […]

Harmony Biosciences Holdings, Inc (NASDAQ:HRMY) Sees Significant Increase in Short Interest

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 7,090,000 shares, a growth of 5.5% from the April 30th total of 6,720,000 shares. Approximately 23.1% of the shares of the company […]

Needham & Company LLC Reiterates Buy Rating for Merus (NASDAQ:MRUS)

Needham & Company LLC reissued their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $66.00 target price on the biotechnology company’s stock. A number of other analysts also recently commented on the company. Truist Financial started coverage […]

Needham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72 00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. CYTK has been the subject of several other research reports. JMP Securities lowered their price […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.